{
    "clinical_study": {
        "@rank": "75563", 
        "arm_group": [
            {
                "arm_group_label": "Baricitinib", 
                "arm_group_type": "Experimental", 
                "description": "Baricitinib - 10 milligram (mg) tablet administered orally once daily (QD) on Day 1."
            }, 
            {
                "arm_group_label": "Baricitinib + Omeprazole", 
                "arm_group_type": "Experimental", 
                "description": "Baricitinib - 10 mg tablet administered orally QD on Day 10. Omeprazole - 40 mg capsule administered orally QD for 8 days (Days 3 through 10)."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to find out how the body will react to a study drug called\n      baricitinib when taken with another drug called omeprazole.\n\n      For each participant, this study will include 2 periods in fixed order. The study will last\n      approximately 25 days, not including screening."
        }, 
        "brief_title": "A Study of Baricitinib and Omeprazole in Healthy Participants", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Overtly healthy as determined by medical history and physical examination\n\n          -  Women not of childbearing potential due to surgical sterilization (at least 3 months\n             after surgical hysterectomy, bilateral oophorectomy with or without hysterectomy, or\n             bilateral tubal occlusion/ligation) confirmed by medical history, or menopause\n\n          -  Have a body mass index of 18 to 29 kilograms per square meter (kg/m^2), inclusive, at\n             screening\n\n        Exclusion Criteria:\n\n          -  Have known allergies to baricitinib, omeprazole, related compounds, or any components\n             of the baricitinib or omeprazole formulations, or history of significant atopy\n\n          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,\n             gastrointestinal, endocrine, hematological (including clotting disorders), or\n             neurological disorders capable of significantly altering the absorption, metabolism,\n             or elimination of drugs; of constituting a risk when taking the study medication; or\n             of interfering with the interpretation of data\n\n          -  Have an absolute neutrophil count (ANC) less than 2 \u00d7 109 per liter (L) (2000\n             cells/microliter [\u03bcL]) at screening or Day -1. For abnormal values, a single repeat\n             will be allowed\n\n          -  Intend to use over-the-counter or prescription medication (including drugs and\n             substances known to alter gastric potential hydrogen (pH), such as proton pump\n             inhibitors or over-the-counter antacid remedies and/or herbal supplements within 14\n             days prior to dosing and during the study (with the exception of hormone replacement\n             therapy (HRT) and occasional paracetamol, which will be permitted at the discretion\n             of the investigator), or intended use of vitamin supplements from Day 1 until\n             discharge from the clinical research unit (CRU)\n\n          -  Have used or intend to use any drugs or substances that are known to be substrates,\n             inhibitors, or inducers of cytochrome P450 3A4 (CYP3A4) within 30 days prior to\n             dosing and throughout the study\n\n          -  Are unable to tolerate or unwilling to undergo insertion of a nasogastric pH probe\n             for assessment of gastric pH during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925144", 
            "org_study_id": "14603", 
            "secondary_id": "I4V-MC-JAGF"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Baricitinib", 
                    "Baricitinib + Omeprazole"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Baricitinib", 
                "intervention_type": "Drug", 
                "other_name": "LY3009104"
            }, 
            {
                "arm_group_label": "Baricitinib + Omeprazole", 
                "description": "Administered orally", 
                "intervention_name": "Omeprazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Omeprazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leeds", 
                    "country": "United Kingdom", 
                    "state": "West Yorkshire", 
                    "zip": "LS2 9LH"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Impact of Increased Gastric pH Following Omeprazole Administration on the Absorption of Baricitinib in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 10, predose through 48 hours post dose"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (tmax) of Baricitinib", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 10, predose through 48 hours post dose"
            }, 
            {
                "measure": "Pharmacokinetics, Area Under the Plasma Concentration-Time Curve From Time 0 Hour (h) to Infinity (AUC0-\u221e) of Baricitinib", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 10, predose through 48 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925144"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}